Ministerio de Ciencia e Innovación

Breast and Gynecological Cancers

Coordinator:  Joaquín Arribas / Co-coordinator: Gema Moreno

Breast cancer is the most incident type of cancer among women in our country and the leading cause of cancer-related death in European women. Gynecological cancer encompasses any cancer that affects a woman's reproductive system, including cervical, ovarian, uterine, vaginal, and vulvar cancers, among others.

Although the survival of patients with these types of cancer has increased in recent years, a fraction of them, especially those in a metastatic state, remains incurable. For this reason, a deeper understanding of the mechanisms involved in their progression and the lack of response to current treatments is necessary.

The CIBERONC Breast and Gynecological Cancers Program integrates seven multidisciplinary and collaborative research groups specialized in these pathologies to address their main issues from basic science to clinical aspects.

Program objective:

  • Targeting the tyrosine kinase receptor signaling pathway as a therapeutic target: biomarkers, new therapies, and mechanisms of resistance.

New therapies, resistance to drugs and mechanisms connected with the physiopathology of breast cancer


Jefe de GrupoInstitución consorciadaCCAA
Emilio Alba Universidad de Málaga Málaga
Atanasio Pandiella Centro de Investigación del Cáncer Salamanca
Joan Albanell Hospital del Mar Cataluña
Gema Moreno Universidad Autónoma de Madrid Madrid
José Palacios Hospital Ramón y Cajal Madrid
Joaquín Arribas Hospital del Mar Cataluña
Miguel Martín Hospital Gregorio Marañón Madrid

This program is primarily focused on two of the neoplastic typologies with the greatest social impact due to their high mortality rate and aggressiveness: colon cancer and pancreatic cancer.

Colon cancer is the most common cancer in Spain and the second leading cause of cancer-related deaths. The survival of patients with this type of cancer depends on the stage at diagnosis, with survival rates not exceeding 20% in stage IV cases. On the other hand, pancreatic ductal adenocarcinoma is one of the most aggressive cancers, ranking as the fourth leading cause of cancer-related deaths, despite accounting for only 10% of gastrointestinal tumors.

Recognizing the significant technological and scientific advancements that have occurred in recent years in diagnosing and treating these diseases, there are still significant clinical challenges to be addressed.

This program combines the potential of 9 research groups of internationally recognized prestige to deepen our understanding of the (epi)genomic characteristics of neoplastic cells and their interaction with the tumor microenvironment in order to improve clinical stratification, both in patients with mutations predisposing them to the development of these cancers and in patients who have already developed the disease.